Establishment Labs Holdings Inc. (NASDAQ: ESTA)

Establishment Labs Holdings Inc. is a global medical technology company focused on improving patient safety and aesthetic outcomes in the breast aesthetics and reconstruction market. Its core product line is the Motiva Implants silicone gel filled breast implants which incorporate proprietary technologies such as SilkSurface SmoothSilk Qid ZEN RFID BluSeal visual barrier layer and TrueMonobloc gel shell patch configuration. The company offers five product families of Motiva Implants including Round and Ergonomix Round Ergonomix Oval Anatomical TrueFixation Ergonomix2 Round and Ergonomix2 Diamond and Flora Tissue Expander. In addition to implants Establishment Labs markets the Motiva Flora tissue expander and minimally invasive technologies such as Preservé and Mia Femtech. Motiva Implants have received PMA approval from the FDA for sale in the United States and CE marks for distribution in Europe and other international markets. To date the company has sold over 4,800,000 breast implants in more than 100 countries. Post market surveillance data shows rupture, capsular contracture, and reoperation rates each below 0.1% for its Motiva Implants.

The company generates revenue principally from the sale of its Motiva Implants which accounted for approximately 99% of total sales in 2025 and 96% in 2024. Revenue comes through two main channels sales to independent medical device distributors and direct sales to physicians hospitals and clinics. Additional revenue streams are derived from the sale of the Motiva Flora tissue expander and from minimally invasive products such as Preservé and Mia Femtech. While the majority of sales are denominated in euros Brazilian reais and British pounds the company reports its financial results in US dollars. Establishment Labs invested $20,200,000 in research and development during the fiscal year ended December 31 2025 supporting ongoing product innovation and clinical studies. As of December 31 2025 the company employed 1,004 people worldwide and its sales organization consisted of 278 employees and contractors. The company’s manufacturing capacity was expanded in 2024 with the completion of the Sulàyöm Innovation Campus which added approximately 730,000 implants per year of production capability.

Establishment Labs Holdings Inc. competes in the global breast implant market against major rivals such as Allergan Aesthetics AbbVie Mentor Worldwide LLC Johnson & Johnson and Sientra Inc. The worldwide breast augmentation market saw about 1,700,000 procedures in 2024 while the reconstruction market was valued at $2,160,000,000 the same year. The company distinguishes itself through proprietary safety features lower reported complication rates and a vertically integrated manufacturing base in Costa Rica. Its strong patent portfolio includes over 200 issued patents and pending applications covering implant barrier layers surface texture minimally invasive delivery systems and RFID technology. Establishment Labs focuses on innovative minimally invasive procedures such as Preservé and Mia Femtech which expand its product suite beyond traditional implants. These differentiators provide competitive advantages despite the larger scale and broader distribution networks of its competitors. The reconstruction market is projected to grow at a compound annual growth rate of 6.7% from 2025 to 2030 reaching an estimated value of $3,150,000,000 by 2030. Motiva Implants are noted for low rates of adverse events including rupture, capsular contracture, and reoperation that compare favorably with those of legacy competitors.

The company serves a diverse customer base that includes independent medical device distributors hospitals outpatient surgery centers and individual plastic surgeons and clinics. Its products are available in over 100 countries with direct sales operations in key markets such as the United States Brazil Argentina and several European nations. In the United States the company sells directly to hospitals ambulatory surgery centers and private practices. In Brazil and Argentina Establishment Labs maintains a direct sales force that engages with surgeons and clinics. In several European countries the company also uses a direct sales approach while relying on exclusive distributors in the remaining markets. As of December 31 2025 the sales organization included 278 employees and contractors supporting distributor relationships and direct sales efforts. Establishment Labs works with a network of exclusive distributors that cover regions ranging from Latin America to Asia Pacific and the Middle East.